Updated

Amgen shares fell roughly 5% following news related to a competitor's Lp(a)-targeting drug, raising questions about the competitive outlook for Amgen's own cardiovascular pipeline despite the news not directly involving Amgen's own product. The move highlights how clinical developments from rival drugmakers can weigh on Amgen's stock even when its own late-stage assets are not directly implicated.